Equities analysts forecast that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post sales of $4.30 billion for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings. The lowest sales estimate is $4.18 billion and the highest is $4.38 billion. Teva Pharmaceutical Industries posted sales of $4.56 billion during the same quarter last year, which suggests a negative year-over-year growth rate of 5.7%. The company is expected to announce its next quarterly earnings report on Wednesday, February 12th.
According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year sales of $17.24 billion for the current fiscal year, with estimates ranging from $17.13 billion to $17.36 billion. For the next fiscal year, analysts expect that the firm will post sales of $17.07 billion, with estimates ranging from $16.63 billion to $17.76 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The business had revenue of $4.34 billion during the quarter, compared to the consensus estimate of $4.25 billion. During the same quarter in the prior year, the firm earned $0.78 earnings per share. The business’s quarterly revenue was down 7.7% compared to the same quarter last year.
Several equities research analysts have recently weighed in on TEVA shares. Guggenheim started coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 12th. They set a “neutral” rating for the company. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Friday. Raymond James decreased their target price on shares of Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Wells Fargo & Co decreased their target price on shares of Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating for the company in a research note on Monday, September 30th. Finally, UBS Group set a $8.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Friday, August 16th. Six equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $10.78.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Point View Wealth Management Inc. increased its holdings in Teva Pharmaceutical Industries by 1.7% in the second quarter. Point View Wealth Management Inc. now owns 74,798 shares of the company’s stock valued at $690,000 after buying an additional 1,273 shares in the last quarter. CAPROCK Group Inc. increased its holdings in Teva Pharmaceutical Industries by 6.2% in the third quarter. CAPROCK Group Inc. now owns 23,730 shares of the company’s stock valued at $163,000 after buying an additional 1,378 shares in the last quarter. AdvisorNet Financial Inc increased its holdings in Teva Pharmaceutical Industries by 71.3% in the third quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after buying an additional 1,525 shares in the last quarter. Northstar Group Inc. increased its stake in shares of Teva Pharmaceutical Industries by 8.4% during the 2nd quarter. Northstar Group Inc. now owns 20,568 shares of the company’s stock worth $190,000 after purchasing an additional 1,600 shares in the last quarter. Finally, AGF Investments America Inc. increased its stake in shares of Teva Pharmaceutical Industries by 1.9% during the 2nd quarter. AGF Investments America Inc. now owns 91,897 shares of the company’s stock worth $848,000 after purchasing an additional 1,672 shares in the last quarter. 58.21% of the stock is owned by hedge funds and other institutional investors.
Shares of TEVA traded up $0.83 during mid-day trading on Thursday, hitting $9.30. 34,192,717 shares of the company’s stock were exchanged, compared to its average volume of 16,922,125. Teva Pharmaceutical Industries has a fifty-two week low of $6.07 and a fifty-two week high of $23.97. The firm has a market capitalization of $9.32 billion, a P/E ratio of 3.32, a P/E/G ratio of 0.89 and a beta of 1.73. The business’s 50 day moving average is $7.51 and its two-hundred day moving average is $8.90. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: What is the outlook for the FAANG stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.